Former Grantee of Record: Community Medical Services.

Original Period of Grant Support: March 1, 2009 to February 28, 2011 (NAP); March 27, 2009 to March 26, 2011 (IDS); and June 29, 2009 to June 28, 2011 (CIP).

Replacement Awardee: Cornerstone Care, Inc.

Amount of Replacement Awards: \$391,306 (NAP), \$101,000 (IDS) and \$250,000 (CIP).

Period of Replacement Awards: The period of support for the replacement awards is March 1, 2009 to February 28, 2011 (NAP); March 27, 2009 to March 26, 2011 (IDS); and June 29, 2009 to June 28, 2011 (CIP).

Authority: Section 330 of the Public Health Service Act, 42 U.S.C. 245b. CFDA Number: 93.703.

*Justification for the Exception to Competition:* 

The former grantee, Community Medical Services (CMS), Inc., is unable to meet several Health Center Program statutory and regulatory requirements. CMS notified HRSA that it was unable to carry out the administrative and programmatic requirements to appropriately manage the grant funds and indicated that it would be relinquishing the grant funds. CMS's inability to meet these requirements has restricted it from providing necessary primary health care services in Favette County, Pennsylvania, to the more than 10,500 low income, underserved and uninsured individuals in the service area, as had been proposed in their approved New Access Point grant application.

Cornerstone Care Inc. (CCI) is an experienced provider of care and is currently providing primary health care services under a contractual agreement with CMS to the original target population, has a demonstrated record of compliance with the Health Center Program statutory and regulatory requirements and is located in the same geographical area.

This underserved target population has an immediate need for vital primary health care services and would be negatively impacted by any delay or disruption of services caused by a competition. As a result, in order to ensure that critical primary health care services remain available to the original target population without disruption, this replacement award will not be competed.

### FOR FURTHER INFORMATION CONTACT:

Marquita Cullom-Stott via e-mail at *MCullom-Stott@hrsa.gov* or 301–594–4300.

Dated: April 16, 2010.

#### Marcia K. Brand,

Deputy Administrator.

[FR Doc. 2010-9308 Filed 4-21-10; 8:45 am]

BILLING CODE 4165-15-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

## Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society

Pursuant to Public Law 92–463, notice is hereby given of the twenty-second meeting of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8:30 a.m. to approximately 5:30 p.m. on Tuesday, June 15, 2010, and from 8 a.m. to approximately 2:45 p.m. on Wednesday, June 16, 2010, at the Washington Plaza Hotel, 10 Thomas Circle, NW., Washington, DC 20005. The meeting will be open to the public with attendance limited to space available. The meeting will also be Web cast.

The main agenda item will be an exploratory session on the implications of affordable whole-genome sequencing. The meeting will also include updates and discussions on other issues SACGHS has been addressing, including the work of the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children related to the retention and use of dried blood spot specimens from newborn screening.

As always, the Committee welcomes hearing from anyone wishing to provide public comment on any issue related to genetics, health and society. Please note that because SACGHS operates under the provisions of the Federal Advisory Committee Act, all public comments will be made available to the public. Individuals who would like to provide public comment should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at 301-496-9838 or e-mail at carrs@od.nih.gov. The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, is also asked to contact the Executive Secretary.

Under authority of 42 U.S.C. 217a, section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic and genomic technologies and, as warranted, to provide advice on these issues. The draft meeting agenda and other information about SACGHS, including information about access to the Web cast, will be available at the following Web site: http://oba.od.nih.gov/SACGHS/sacghs meetings.html.

Dated: April 16, 2010.

### Jennifer Spaeth,

Director, NIH Office of Federal Advisory Committee Policy.

[FR Doc. 2010-9311 Filed 4-21-10; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **National Institutes of Health**

# National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Drug Discovery, Chemoprevention and Targeted Therapy.

Date: May 25–27, 2010. Time: 8 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Peter J. Wirth, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8129, Bethesda, MD 20892–8328. 301–496– 7565.pw2q@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science.

Date: June 14, 2010.
Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.